![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
Abstract
Objectives: Antipsychotics are effective in treating psychosis and mood episodes; however, the effect on cognition is less known. We investigated the association between serum levels of second-generation antipsychotics (SGAs) and cognitive performance in psychosis spectrum disorders in a naturalistic setting.
Methods: A total of 495 patients with a DSM-IV Schizophrenia and Other Psychotic Disorders (SCZ, n = 373) or Bipolar Disorder (BD, n = 122) diagnosis treated with olanzapine, quetiapine, aripiprazole or risperidone were tested neuropsychologically with concurrent measurement of the serum concentration of the drug. Linear regression was used for association analyses.
Results: Attention was positively associated with the olanzapine concentration (standardised beta (β) coefficient = 0.19, P = .006), and short-term verbal memory and verbal fluency were negatively associated with the quetiapine (β = –0.24, P = .004) and risperidone (β = –0.37, P = .007) concentrations respectively.
Conclusions: The present results suggest that SGA serum concentration is associated with better attention (small effect size), and worse verbal memory (small effect size) and verbal fluency (medium effect size). These findings are in line with the notion that SGAs affect aspects of cognitive function, and suggest careful dosing in patients with severe memory and executive problems.
Acknowledgements
The authors thank the patients for participating in the study, and the TOP study group members for contributing with data collection.
Disclosure statement
Nils Eiel Steen, Monica Aas, Carmen Simonsen, Ingrid Dieset, Mari Nerhus, Erlend Gardsjord, Ragni Mørch, Ingrid Agartz, Ingrid Melle and Olav Spigset reported no conflicts of interest. Martin Tesli has received speakers bureau honoraria from Medivir, Torill Ueland has served as an advisory board member for Abbvie, and Ole A. Andreassen has received speakers honorarium from GSK, Lundbeck, Lilly and Otsuka.